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The TIM22 protein import pathway mediates the import of mem-
brane proteins into themitochondrial innermembrane and consists
of two intermembrane space chaperone complexes, the Tim9-Tim10
and Tim8-Tim13 complexes. To facilitate mechanistic studies, we
developed a chemical-genetic approach to identify small molecule
agonists that caused lethality to a tim10-1 yeast mutant at the
permissive temperature. One molecule, MitoBloCK-1, attenuated
the import of the carrier proteins including the ADP/ATP and phos-
phate carriers, but not proteins that used the TIM23 or the Mia40/
Erv1 translocation pathways. MitoBloCK-1 impeded binding of the
Tim9-Tim10 complex to the substrate during an early stage of
translocation, when the substrate was crossing the outer mem-
brane. As a probe to determine the substrate specificity of the small
Tim proteins, MitoBloCK-1 impaired the import of Tim22 and
Tafazzin, but not Tim23, indicating that the Tim9-Tim10 complex
mediates the import of a subset of inner membrane proteins.
MitoBloCK-1 also inhibited growth of mammalian cells and import
of the ADP/ATP carrier, but not TIM23 substrates, confirming that
MitoBloCK-1 can be used to understand mammalian mitochondrial
import and dysfunction linked to inherited human disease. Our
approach of screening chemical libraries for compounds causing
synthetic genetic lethality to identify inhibitors of mitochondrial
protein translocation in yeast validates the generation of new
probes to facilitate mechanistic studies in yeast and mammalian
mitochondria.
chemical biology ∣ chemical genetics
The mitochondrion has an outer (OM) and inner (IM) mem-brane that separates the matrix from the intermembrane
space (IMS). The mitochondrion has developed an elaborate
translocation system to orchestrate the import and subsequent
sorting of proteins to the correct compartment (1). Proteins des-
tined for the mitochondrion, termed precursors until they reach
their correct location, utilize Translocase of the Outer Membrane
(TOM) and Translocase of the Inner Membrane (TIM) com-
plexes, TIM23 and TIM22, to cross the OM and IM, respectively.
Proteins with a typical N-terminal targeting sequence use the
TIM23 translocation system, whereas proteins destined for the
IM use the TIM22 translocation system.
Components of the TIM22 translocation system include the
small Tim proteins, Tim8, Tim9, Tim10, Tim12, and Tim13, and
the membrane components Tim18, Tim22, and Tim54. The small
Tim proteins assemble in 70-kDa hexameric complexes (referred
to as small Tim complexes) in the IMS in which three Tim9 poly-
peptides partner with three Tim10 polypeptides, and three Tim8
polypeptides partner with three Tim13 polypeptides. Structural
studies reveal that the overall structure is similar to that of the
Skp and prefoldin chaperones (2), although the sequences are
not conserved. The small Tim proteins function as chaperones
to maintain the hydrophobic membrane proteins in an import
competent state (3 and 4). The 300-kDa insertion complex in
the IM consists of a fraction of Tim9 and Tim10 with Tim12,
Tim22, Tim18, and Tim54. The small Tim proteins escort sub-
strates to the insertion complex, which mediates protein insertion
into the membrane.
Substrates of the TIM22 complex include the carrier proteins
such as the ADP/ATP carrier (AAC) and the phosphate carrier
(PiC) and IM proteins Tim17, Tim22, and Tim23. In addition, the
small Tim proteins facilitate the insertion of outer membrane
proteins Tom40 and porin and the cardiolipin remodeling enzyme
Tafazzin (5–7). The substrates cross the TOM complex as a loop
in an unfolded state and then the small Tim proteins bind to the
substrate at an early stage of translocation (4, 8, 9).
The Tim8-Tim13 and Tim9-Tim10 complexes display different
substrate binding preferences. The Tim9-Tim10 complex can be
efficiently cross-linked to carrier proteins and the import compo-
nents Tim17, Tim23, and Tim22 (10–12). The Tim8-Tim13 com-
plex can be cross-linked to Tim23 and the aspartate–glutamate
carriers (10–13). Mutations in the human homolog of Tim8,
DDP1, cause the X-linked disease deafness-dystonia syndrome
(14 and 15), and the disease may be caused by a decrease in spe-
cific IM proteins (13). Therefore, understanding the substrate
specificity of the small Tim proteins is important for understand-
ing the molecular basis of deafness-dystonia syndrome.
Mitochondrial assembly has been studied extensively using
classical yeast genetics and biochemical assays with purified mi-
tochondria. However, new strategies are needed to elucidate the
details of protein translocation and its role in development and
human disease. Important questions about the substrate speci-
ficity of the small Tim proteins and the mechanism by which the
small Tim proteins bind substrate have not been resolved. These
studies would be facilitated by drug-like inhibitors that modulate
protein import. Here we report the development of a small mo-
lecule screening approach to identify inhibitors of the TIM22
import pathway. Taking advantage of our large collection of
temperature-sensitive mutants for the TIM22 import pathway,
we conducted a chemical-genetic screen with a tim10-1 mutant
to identify small molecules that caused a synthetic lethality at
the permissive temperature of 25 °C (16–19). Our results indicate
that a new set of tools for mechanistic studies in protein translo-
cation can be developed and may be useful for characterizing
protein translocation in mammalian mitochondria, where tools
are lacking.
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Results
A Screen to Identify Inhibitors of Mitochondrial Protein Translocation.
We exploited a large collection of temperature-sensitive mutants
for the TIM22 import pathway (10, 16–18) and developed a
composite synthetic lethal screen to identify small molecule inhi-
bitors that blocked the TIM22 import pathway (19). The tim10-1
mutant was used as the starting strain (16); the strains used in this
study are described in Table S1. The rationale in this screen was
that small molecules might be identified that target the mutant
Tim10 protein or other components of the TIM22 pathway and
thereby cause lethality of the tim10-1 mutant at the permissive
temperature of 25 °C. This approach uses the well characterized
synthetic growth defects of the tim10-1mutant to guide the design
of cells genetically sensitized for inhibition of the TIM22 pathway.
To generate a suitable strain for screening, genes for the multi-
drug resistance pumpsPDR5 andSNQ2were disrupted to increase
the steady-state intracellular concentration of the drugs in yeast
(19). The tim10-1 mutant grew similar to the parental strain (de-
signated TIM10) at 25 °C but failed to grow at the restrictive tem-
perature of 37 °C (Fig. 1A). Growth was inhibited on media that
contained glucose (YPD, supporting fermentable growth) or etha-
nol-glycerol (YPEG, supporting nonfermentable growth) as the
sole carbon source. We verified that the abundance of the mutant
Tim10 was decreased in the tim10-1 strain; however, the abun-
dance of other mitochondrial proteins was not markedly de-
creased in mitochondria when the strain was grown at 25 °C
(Fig. S1A) (16). In addition, deletion of the multidrug resistance
pumps did not compromise growth or the mitochondrial protein
profiles of the tim10-1 mutant. In contrast, when we investigated
assembly of the soluble 70 kDa Tim9-Tim10 complex in the tim10-
1 mutant, the complex was not detected by immunoblot analysis
(Fig. S1B). Moreover, in vitro import of the TIM22 pathway
substrate, AAC, was inhibited in comparison to mitochondria
from the parental strain (Fig. 1B). The tim10-1 mutant thus has
excellent growth properties for conducting a synthetic genetic
screenwith small compounds to target theTIM22 import pathway.
For subsequent testing of the compounds in biochemical assays
with isolated mitochondria, a suppressor strain, designated
tim10-1 tim9S, was used because growth of the tim10-1 mutant
(Fig. 1A) and import of the carrier proteins were restored
(Fig. 1B). Suppression in this strain is caused by a Ser → Cys mu-
tation in Tim9; the mutated serine residue is nine amino acids
after the second CX3C motif (17). Whereas the specific mecha-
nism of suppression is not understood, the mutant Tim9 protein
restored the abundance of Tim10 (Fig. S1A) and the assembly of
Tim9-Tim10 complexes, albeit of aberrant sizes (Fig. S1B).
The screen was conducted with an integrated robotic system
with plate scheduling. Briefly, diversity oriented commercial li-
braries of drug-like compounds from Chembridge and Asinex
were screened against the tim10-1 strain at a concentration of ap-
proximately 10 μM. The screen encompassed a total of approxi-
mately 40,000 compounds dissolved in DMSO. Yeast in YPD
medium was aliquoted into 384-well plates followed by com-
pound addition with robotic pinning into the assay wells. DMSO
was the vehicle for the small molecules, and several plate columns
that contained only 1% DMSO were included as a control with
the pinned compounds. As a negative control for growth, wells
pinned with the mitochondrial uncoupler carbonyl cyanide
3-chlorophenylhydrazone (CCCP), which caused lethality, were
also included. After 2 d of incubation at 25 °C, cultures in each
well were measured for optical density (OD) as a measure of
growth. A typical reading for the positive control was
OD600 ¼ 0.7. Wells in which the growth was inhibited by >50%
were deemed as potential inhibitors and chosen for further
analysis. Approximately 600 inhibitors from the primary screen
were selected for hit confirmation and secondary screens.
To identify possible specific inhibitors of mitochondrial protein
translocation from the pool of hit compounds, two counter
screens were executed. In the first round, the initial hit com-
pounds were incubated with the tim10-1 mutant and the isogenic
control strain carrying an integrated version of the TIM10 gene at
the leu2 locus. Small molecules that inhibited growth of the mu-
tant but not the control strain at 10 μM were advanced to the
second counter screen. In a second round, compounds were as-
sayed for selective growth inhibition of the tim10-1 mutant, but
not the tim10-1 mutant harboring a plasmid containing the wild-
type TIM10 gene. The second counterscreen was a test for
chemical-genetic rescue. Compounds that showed inhibition of
only the tim10-1 mutant in both counter screens were dubbed
“MitoBloCK” compounds based on their potential to inhibit
protein translocation in mitochondria. Of 25 potential “lead”
inhibitors, MitoBloCK-1 was chosen for additional analysis.
MitoBloCK-1 Inhibits Protein Import of TIM22 Substrates into Mito-
chondria. MitoBloCK-1 is a tetrahydrodibenzofuran derivative
that was identified from the Chembridge library (Fig. 2A). The
MIC50 for MitoBloCK-1 that inhibited growth of the tim10-1
mutant was approximately 1 μM (Fig. 2B). MitoBloCK-1 had a
similar MIC50 with another temperature-sensitive tim10 mutant,
tim10-73. In contrast, the MIC50 for the isogenic control was
greater than 200 μM. To understand the cell-based activity of
MitoBloCK-1, we also determined the MIC50 with other yeast
mutants that also were disrupted for prd5 and snq2 (Table 1).
For mutants within the TIM22 pathway, MitoBloCK-1 displayed
an MIC50 concentration of 11 μM for the tim9-3 mutant and
10 μM for the tim10-1 tim9S suppressor strain, respectively. In
contrast, the MIC50 for MitoBloCK-1 in the tim23 mutant was
Fig. 1. Phenotypic analysis of the strains used for the chemical synthetic-leth-
ality screen for inhibitors of the TIM22 protein import pathway. (A) Growth
phenotypes of the control (TIM10), the tim10-1mutant, and tim10-1 suppres-
sor (tim10-1 tim9S) strains used in the screen. Strains were plated on rich
glucose (YPD) or ethanol-glycerol (YPEG) media and incubated at 25 °C or
37 °C. All of these strains were isogenic except for their denoted genetic
variation. (B) Radiolabeled AAC was imported into isolated mitochondria in
the presence and absence of a membrane potential (Δψ). Aliquots were
removed at the indicated time points and samples were treated with
carbonate extraction to confirm that AAC was inserted into the IM.








greater than 200 μM. Overexpression of import components,
TIM8, TIM9, TIM13, TIM22, and TIM23, in the tim10-1 mutant
did not alter the ability of MitoBloCK-1 to inhibit growth. Inter-
estingly, strains lacking the mitochondrial genome (denoted
as rho null) were also sensitive to MitoBloCK-1. Thus, Mito-
BloCK-1 specifically inhibited growth of the tim9 and tim10
mutants, even in the presence of the suppressing mutation in
Tim9; this growth analysis suggests MitoBloCK-1 targets the
Tim9-Tim10 complex.
The ability of MitoBloCK-1 to inhibit import of mitochondrial
precursors was tested using the in vitro import assay with radiola-
beled substrates. For this analysis, mitochondria from the tim10-1
tim9S strain were used because MitoBloCK-1 inhibited growth of
this strain (Table 1) and import of the model substrate, AAC, was
restored in comparison to the tim10-1 mutant (Fig. 1B). An im-
port time course was performed in the presence of the vehicle
DMSO or varying concentrations of MitoBloCK-1 (Fig. 3). In
the presence of DMSO, the import of the TIM22 substrate, AAC,
was not inhibited. However, AAC import was markedly
decreased in the tim10-1 tim9S mitochondria in the presence
of 1 μM MitoBloCK-1 or greater (Fig. 3A). In contrast,
MitoBloCK-1 did not inhibit import into WT mitochondria
(Fig. S2). Thus, the MIC50 in the import assays agree well with
the cell growth assays (Table 1 and Fig. 2B).
MitoBloCK-1 also inhibited the import of an additional carrier
protein, PiC, and the outer membrane protein Tom40, which
requires the small Tim proteins for import (7) (Fig. 3 B, C).
However, for dihydrofolate reductase (DHFR) fusion constructs
Su9-DHFR and cyt b2-DHFR as well as Hsp60 that use the
TIM23 pathway, MitoBloCK-1 did not impair import (Fig. 3D,
S3 A, B). In addition, the import of substrates Tim9, Tim10,
and Mia40 that use the Mia40/Erv1 import pathway (20) was
not inhibited in the presence of MitoBloCK-1 (Fig. S3 C–E).
Finally, MitoBloCK-1 did not inhibit the import of AAC into
tim12-1 mutant mitochondria (16), indicating that import inhibi-
tion is specific for the tim10-1 mutant (Fig. S3F). Therefore,
MitoBloCK-1 seems to specifically block the import of the carrier
proteins and Tom40, which rely on the TIM22 pathway for
translocation.
MitoBloCK-1 Does Not Nonspecifically Damage Mitochondria. A
potential mechanism by which MitoBloCK-1 may inhibit pro-
tein translocation indirectly is by the disruption of oxidative
phosphorylation or dissipation of the membrane potential. We
therefore used a battery of tests to determine if MitoBloCK-1
nonspecifically altered mitochondrial integrity or function. As
a first test, the ability of MitoBloCK-1 to interfere with respira-
tion was measured (Fig. S4A–C) (21). Mitochondria were incu-
bated in a chamber with an oxygen electrode and respiration was
initiated by the addition of NADH. The rate of oxygen consump-
tion was representative of mitochondria that were well coupled.
The subsequent addition of vehicle DMSO (Fig. S4A) or 25 μM
MitoBloCK-1 (∼25-fold above the biochemical MIC50) did not
significantly alter the rate of respiration (Fig. S4A–C) (p ¼ 0.72).
As a control, mitochondria were treated with the proton iono-
phore CCCP; and respiration increased drastically, indicative
of uncoupled mitochondria (Fig. S4A–C).
The membrane potential (Δψ) of mitochondria was measured
with the fluorescent dye rhodamine 123, which is taken up by
mitochondria and then released when the Δψ is dissipated (22
and 23). The relative change of fluorescence between dye uptake
and release is a relative measure of theΔψ ; the dye that loads into
coupled mitochondria (causing quenching and a decrease in
fluorescence) is released when treated with an uncoupling agent
such as CCCP (causing an increase in fluorescence). The fluor-
escence did not change with addition of either DMSO (Fig. S4D)
or 25 μM MitoBloCK-1 (Fig. S4E) in contrast to the sharp in-
crease in fluorescence upon CCCP addition. Taken together, the
oxygen electrode and dye uptake assays support that MitoBloCK-
1 is not a mitochondrial uncoupler.
Another potential mechanism that may alter protein translo-
cation is that the small molecules may nonspecifically permeabi-
lize mitochondrial membranes, and proteins may be released
from the mitochondrion, particularly those in the IMS. We there-
fore incubated mitochondria with MitoBloCK-1 for 30 min fol-
lowed by centrifugation at 8,000 x g (Fig. S4 F, G). Released
proteins were recovered in the supernatant fraction and analyzed
by immunoblot assays for key proteins and Coomassie staining for
the collective release of proteins. As a positive control, Mito-
BloCK-2, another compound from the screen that permeabilized
mitochondrial membranes, was included. Immunoblots revealed
that the release of marker proteins Tom40 (OM), cytochrome c
and Tim10 (IMS), AAC (IM), and Hsp60 (matrix) was similar
when mitochondria were treated with MitoBloCK-1 or DMSO
(Fig. S4F). In contrast, MitoBloCK-2 treatment resulted in re-
lease of the marker proteins from mitochondria, and Coomassie
blue staining confirmed the extensive release of mitochondrial
proteins (Fig. S4G). Finally, MitoBloCK-1 did not alter steady-
state stability of the Tim9-Tim10 complex because the complex
migrated as a 70 kDa complex in the presence of the small
molecule (Fig. S4H). From the aforementioned analysis, Mito-
BloCK-1 does not alter mitochondrial function or membranes
Fig. 2. MitoBloCK-1 exhibits a chemical synthetic lethality with the tim10-1
mutant. (A) The structure of MitoBloCK-1, a tetrahydrodibenzofuran com-
pound. (B) MIC50 analysis of two tim10 mutants (tim10-1 and tim10-73)
and the parental (TIM10) strain with MitoBloCK-1. Average%survival SD
of n ¼ 3 trials. The R2 value for tim10-1 and tim10-73 curve fits were 0.98
and 0.99, respectively.
Table 1. Chemical-genetic analysis of MitoBloCK-1 activity
Strain MIC50* (μM) MIC50* (mg∕mL)
tim10-1 rho null 0.75 ± 0.02 0.28 ± 0.01
tim10-1 1.00 ± 0.05 0.37 ± 0.03
tim10-73 2.00 ± 0.06 0.74 ± 0.02
tim9-3 11.34 ± 1.56 4.18 ± 0.57
tim23-1 >200 >74
TIM10 rho null 12.39 ± 0.9 4.56 ± 0.33
TIM10 >200 >74
tim10-1 TIM10 >200 >74
tim10-1 tim9S 9.91 ± 0.24 3.65 ± 0.09
tim10-1 TIM9 (2μ) 1.48 ± 0.08 0.54 ± 0.03
tim10ts TIM8 (2μ) 2.42 ± 0.15 0.89 ± 0.05
tim10-1 TIM13 (2μ) 1.26 ± 0.03 0.46 ± 0.01
tim10-1 TIM22 (2μ) 8.35 ± 0.27 3.07 ± 0.1
tim10-1 TIM23 (2μ) 1.37 ± 0.04 0.51 ± 0.02
*mean s:d: (n ¼ 3).
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nonspecifically and seems to be a specific inhibitor of protein
import for the TIM22 pathway.
MitoBloCK-1 Impairs Substrate Binding by the Tim9-Tim10 Complex.
MitoBloCK-1 can be used for mechanistic studies in protein
translocation. From our previous analysis of the tim10-1 and
tim12-1 mutants, we showed that Tim10 was required to mediate
translocation of AAC across the outer membrane and Tim12 was
required at a later step to mediate insertion of the AAC into the
IM (16); this analysis was determined by monitoring protease
sensitivity of the AAC precursor. We adapted this methodology
to determine where MitoBloCK-1 impaired AAC translocation.
In wild-type mitochondria, a small fraction of the AAC was
trapped in the IMS when protease was added to mitochondria
in the absence of a membrane potential (Fig. 4A, lane 4). How-
ever, in tim10-1 mutant mitochondria, AAC failed to enter the
IMS. Therefore, AAC that accumulated at the outer membrane
was degraded upon protease addition (Fig. 4A, lane 6, 8), con-
firming that Tim10 is required for a very early step in protein
translocation (24 and 25). We added MitoBloCK-1 in this assay.
In the presence of MitoBloCK-1, AAC was sensitive to protease
in the presence of a membrane potential (Fig. 4A, lane 12), simi-
lar to that of the tim10-1 mutant (Fig. 4A, lane 6). This result
implies that MitoBloCK-1 blocks protein translocation at a step
similar to the block observed with the tim10-1 mutant, namely
translocation across the outer membrane.
The early obstruction in protein translocation by MitoBloCK-1
suggested that binding between the Tim9-Tim10 complex and sub-
stratemight be abrogated.We have previously used a cross-linking
and immunoprecipitation approach in tim10-1 tim9S mitochon-
dria to show that Tim9 binds to substrate during translocation
(18).MitoBloCK-1was therefore added to import assays that were
subjected to cross-linking and immunoprecipitation (Fig. 4B).
In the absence of MitoBloCK-1, antibodies against Tim9
immunopreciptated a cross-linked product between Tim9 and
AAC (Fig. 4B, lane 9). However, the presence of MitoBloCK-1
altered the cross-linking pattern such that the cross-link to
Tim9 decreased in abundance (Fig. 4B, compare lane 4,6);
instead another cross-linked band, indicative of an interactionwith
another protein, became more prevalent (Fig. 4B, lane 6 denoted
by *). Following immunoprecipitation, the cross-linked Tim9-
AAC product was decreased in the presence of MitoBloCK-1
(Fig. 4B, compare lane 9, 12). Additional immunoprecipitation
assays with antibodies against Tom22 and Tom40 failed to immu-
noprecipitate cross-linked AAC, regardless of whether Mito-
BloCK-1 was present. This lack of cross-linking may indicate
that the homobifunctional crosslinker BMH, which is reactive
to free sulfhydryls, did not have adequate sites for reactivity.
As an additional control, AAC with uncoupled mitochondria
(incubated with CCCP) lacked abundant cross-links (Fig. 4B,
lane 5). Therefore, this analysis supports that MitoBloCK-1
impedes protein translocation at an early stage by obstructing
the substrate binding site of the Tim9-Tim10 complex.
MitoBloCK-1 Can Be Used to Determine Substrates of the Tim9-Tim10
Complex. A central question about the TIM22 pathway has been
the specificity of the small Tim complexes. Yeast contain both the
Tim8-Tim13 complex and the Tim9-Tim10 complex and a variety
of studies have suggested that they might have different substrate
specificities (10, 11, 13). Most precursors including the carriers,
Fig. 3. MitoBloCK-1 inhibits the import of substrates that use the TIM22 import pathway. Import assays were performed with radiolabeled precursors into
mitochondria from the tim10-1 tim9S suppressor strain, which has restored import of AAC. Time course assays were completed with various concentrations of
MitoBloCK-1 or the vehicle control (1% DMSO). Nonimported precursor was removed by protease treatment. Precursors include (A) AAC, (B) the phosphate
carrier (PIC), (C) Tom40, and (D) Hsp60, (A–C) represent precursors that use the TIM22 import pathway whereas D is a substrate of the TIM23 import pathway.
p, precursor; m, mature.
Fig. 4. MitoBloCK-1 impairs substrate binding by the Tim9-Tim10 complex.
(A) AAC was imported into mitochondria isolated from TIM10, tim10-1, and
suppressor tim10-1 tim9S strains in the presence and absence of a Δψ . Where
indicated,MitoBloCK-1was included in the tim10-1 tim9Smitochondria. After
importing AAC 15min, reactionswere stoppedwith either cold buffer or tryp-
sin (protease). (B) AAC was imported into tim10-1 tim9S mitochondria in the
presence of 25 μMMitoBloCK-1 or uncoupledmitochondria (lanes 1–3), A frac-
tion of the import reactionwas treatedwith the irreversible cysteine cross-lin-
ker bismaleimidohexane (BMH) (lanes 4–6). BMH-treated samples were
divided and aliquots were subjected to immunoprecipitation (IP) with either
Tim22 (22), Tom40 (40), or Tim9 (9) polyclonal antibodies bound to protein
A-Sepharose beads (lanes 7–12). In addition to the previously characterized
Tim9-AAC cross-link, a second cross-link of approximately 55 kD (denoted
by *) was prevalent in the MitoBloCK-1 and BMH treated sample (lane 6).








Tim22, and Tim17 require the Tim9-Tim10 complex, whereas
Tim23 and the aspartate-glutamate carriers require the Tim8-
Tim13 complex. In addition, the small Tim proteins facilitate
the import of outer membrane proteins (5 and 7). We therefore
examined whether MitoBloCK-1 could be used to determine
substrate specificity of the Tim9-Tim10 complex with precursors
Tim22, Tim23, and Tafazzin (Fig. 5). The import of Tim22 but not
Tim23 was impaired in the presence of MitoBloCK-1, indicating
that Tim23 seems to require the Tim8-Tim13 complex for trans-
location across the outer membrane (Fig. 5 A, B). Tafazzin is a
cardiolipin remodeling enzyme that, when mutated, causes the
inherited disease Barth Syndrome (26). Tafazzin import was
impaired in mitochondria lacking functional Tim10 (6). When
Tafazzin was imported in the presence of MitoBloCK-1, import
was inhibited, confirming a role for the Tim9-Tim10 complex in
the biogenesis of Tafazzin (Fig. 5C). Studies with MitoBloCK-1
thus support a role for the Tim9-Tim10 complex in the import of
Tafazzin and Tim22, but not Tim23.
Taking advantage of commercially available compounds simi-
lar to MitoBloCK-1, we purchased additional compounds for an
abbreviated structure-activity relationship (SAR) study (Fig. 6A).
Similar compounds to MitoBloCK-1 were available in which the
side chain was substituted or the tricyclic ring was changed from a
dihydrobenzofuran to a carbazole. Analogs A and D were similar
to MitoBloCK-1 except that the thiourea of the side chain was
modified. Analogs B and C contained changes in the ring (car-
bazole) as well as the side chain. These compounds were tested
in the import assay and Analog D was the only compound to
inhibit import of AAC but required an increased concentration
of 50 μM (Fig. 6A). A limited SAR analysis showed that pro-
perties of the ring structure and side chain are important for
MitoBloCK-1 activity.
The long-term goal with these MitoBloCK compounds is to
develop small molecules that inhibit protein translocation in
mammalian systems for mechanistic studies and for developing
tools to alter mitochondrial function with the objective of
developing diseasemodels.As a first step, we testedwhetherMito-
BloCK-1 might affect general mitochondrial function in mamma-
lian cells and measured cell viability in mammalian cells using a
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay
(Fig. S5A). Given that mitochondrial protein import is essential
for cell survival, a reduction in translocation would be expected
to reduce cell viability. When cells were treated with 25 μM
and 50 μM MitoBloCK-1, viability significantly decreased in a
dose-responsive manner. We then tested whether MitoBloCK-1
inhibited import into isolated mouse liver mitochondria (Fig. 6B).
In the presence of 25 mM MitoBlock-1, the import of AAC was
inhibited. In contrast, the import of Su9-DHFR and Hsp60 was
not altered in the presence of MitoBloCK-1 (Fig. S5 B, C) Thus,
the addition of MitoBloCK-1 to mammalian mitochondria dis-
rupts the import ofAAC, albeit at a higher concentration thanwith
yeast mitochondria.
Discussion
MitoBloCK-1 is a unique small molecule inhibitor that blocks the
import of substrates that use the TIM22 import pathway. We
started this screen with a genetic approach by developing a
composite synthetic lethal screen to identify small molecules that
inhibited growth of the tim10-1 mutant at the permissive tem-
perature of 25 °C. Although MitoBloCK-1 may have many poten-
tial targets within a yeast cell, we devised a battery of tests using
growth analyses followed by biochemical assays to determine the
specific site of inhibition by MitoBloCK-1. Because the small
molecules may nonspecifically alter mitochondrial function, we
determined its effect on membrane potential, respiration, and
mitochondrial integrity; MitoBloCK-1 does not generally damage
mitochondria. Moreover, import assays showed that import of
TIM22 substrates was specifically inhibited and cross-linking and
immunoprecipitation assays showed that the Tim9-Tim10 com-
plex did not bind to substrate effectively. The combination of
these assays indicated that MitoBloCK-1 inhibits an early step
in protein translocation, when the Tim9-Tim10 complex binds
to substrate during translocation across the outer membrane
(Fig. 6C) (3, 16, 25).
The characterization of MitoBloCK-1 supports that the chemi-
cal-genetic approach is important for developing probes to study
assembly of mitochondrial membranes. Mechanistic studies for
the assembly of outer and IM proteins still need refinement
(1). Our analysis shows that Tim9-Tim10 is important for the
import of Tafazzin, Tom40, the carrier proteins, and Tim22,
but not Tim23, which support that the small Tim complexes have
different substrate specificity (3, 4, 10, 13). Therefore, develop-
Fig. 5. MitoBloCK-1 facilitates substrate specificity analysis. Tim22 (A), Tim23
(B), and Tafazzin (C) were imported into tim10-1 tim9S mitochondria in the
presence of MitoBloCK-1 or the vehicle (1% DMSO) followed by carbonate
extraction to confirm insertion into the membrane.
Fig. 6. MitoBloCK-1 activity is influenced by specific chemical characteristics
and inhibits AAC imported into mammalian mitochondria. (A) Analogs of
MitobloCK-1 were purchased from Chembridge and assayed in import assays
with radiolabled AAC as previously described. (B) AAC was imported into
isolated mouse liver mitochondria in the presence of 25 μM MitoBloCK-1
as in Fig. 3A. (C) Model of MitoBloCK-1 activity from experimental evidence.
See text for more details.
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ment of these probes will yield a new set of tools for studying
mitochondrial membrane biogenesis.
Apotential drawback ofMitoBloCK-1 is that import is inhibited
in the tim10-1 tim9Smitochondria but not wild-typemitochondria.
The small SAR studies suggest that particular properties of Mito-
BloCK-1, such as the length of the side chain and the dihydroben-
zofuran ring, may be important for its function. Therefore
MitoBloCK-1 may serve as a starting point for developing more
potent analogs that inhibit protein import in wild-type yeast mito-
chondria. In addition, the overall structure of the human small Tim
proteins is highly conserved with the yeast homologs (2), and we
clearly show that import into isolated mammalian mitochondria is
inhibited. Following the initial import assays in mammalian mito-
chondria with an extended SAR approach may lead to the refine-
ment of small molecules that inhibit function of the different
mammalian small Tim proteins.
Mitochondria now have been implicated in a wide array of de-
generative diseases including Parkinson’s and Alzheimer’s (27–
30). For example, a defect in import has been linked toAlzheimer’s
when the amyloid precursor protein arrests in the Tom40 translo-
con (30). These latest developments indicate that alteration of
protein translocation pathways may be important for (1) mechan-
istic studies in these diseases and (2) to create model systems to
recapitulate the disease. Thus, having new and specific tools avail-
able such as the MitoBloCK compounds may be important for
broad research in understanding how mitochondrial dysfunction
contributes to disease. The development of small molecule inhi-
bitors also serves as a technological advance over general mito-
chondrial inhibitors (uncouplers and inhibitors of respiration)
that uncouple mitochondria or irreversibly inhibit respiration.
Materials and Methods
High-Throughput Screening. A primary screen was performed using freshly
streaked tim10-1 diluted in YPD to an OD600 of approximately 0.0002 and
kept on ice throughout the screening run. A Titertek multidrop was used
to dispense 40 μL of cell suspension to all wells of each clear 384-well plate
(Greiner Bio One). After yeast suspension warmed to room temperature, a
Biomek FX (Beckman Coulter) was used to pin transfer 0.5 μL of compound
from 1 mM stock or DMSO to respective wells. Approximate screening con-
centration was 12.5 μM. All operations were performed by an automated
plate scheduler to ensure consistency across the screening run. After com-
pleted compound transfer, all plates were incubated at 25 °C in a humidified
incubator until the OD600 reached approximately 0.8 in the control wells; the
control consisted of the tim10-1 mutant with the vehicle 1% DMSO. Each
plate was shaken in a Beckman orbital shaker to resuspend settled cells,
and the OD600 in each well was read by a Wallac Victor plate reader (Perkin
Elmer). The top 600 growth inhibitory compounds were determined and as-
sembled into two plates. Using a similar screening methodology, hit com-
pounds were reconfirmed with the tim10-1 strain and growth inhibition
was compared to the WT strain (TIM10) as well as the “rescued” strain
(tim10-1 TIM10 that contained a copy of the wild-type TIM10 genes on a cen-
tromeric plasmid) strains. Compounds reordered from Asinex and Chem-
bridge were assayed for MIC50 using a similar automated technique in
384-well plates as previously described. Serial dilutions of purchased com-
pounds were performed with robotic automation in 100% DMSO. Subse-
quently, compounds were pinned into assay plate wells containing 50 μL
of the respective yeast strain in YPD medium (starting OD600 ¼ 0.0002).
Growth duration and conditions were similar to the original screen.
Biochemical Assays with Mitochondria and Additional Methods. Detailed meth-
ods are listed in the SI Text.
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